Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6NCya-Prxl2aem1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6NCya-Prxl2aem1flox/Cya

Common Name
Prxl2a-flox
Product ID
S-CKO-14860
Backgroud
C57BL/6NCya
Strain ID
CKOCMP-70564-Prxl2a-B6N-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Prxl2a-flox Mouse (Catalog S-CKO-14860) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Prxl2a-flox
Strain ID
CKOCMP-70564-Prxl2a-B6N-VA
Gene Name
Prxl2a
Product ID
S-CKO-14860
Gene Alias
Adrx, Pamm, Fam213a, 5730469M10Rik
Background
C57BL/6NCya
Gene Full Name
peroxiredoxin like 2A
Modification
Conditional knockout
NCBI ID
70564 (Mouse)
Phenotype
MGI:1917814
Chromosome
Chr 14 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000022317
NCBI Transcript ID
NM_027464
Target Region
Exon 3
Size of Effective Region
~0.6 kb
Overview of Gene Research
Prxl2a, also known as peroxiredoxin like 2A, is an antioxidant protein. It protects cells from oxidative stress and may be involved in multiple biological processes related to redox regulation [1]. Oxidative stress is associated with various disease conditions, highlighting the importance of Prxl2a in maintaining cellular homeostasis.

In oral squamous cell carcinoma (OSCC), miR-125b downregulation leads to Prxl2a upregulation, protecting tumor cells from oxidative stress. Exogenous miR-125b expression in OSCC cells increases oxidative stress and drug sensitivity, similar to Prxl2a knockout, indicating an miR-125b-Prxl2a regulatory axis in OSCC pathogenesis [1].

In endometrial cancer, a prognostic signature including Prxl2a was established. Knockdown of Prxl2a significantly inhibited the proliferation and colony formation of Ishikawa and AN3CA cells, and suppressed xenograft growth [2].

In kidney renal clear cell carcinoma, Prxl2a was identified as one of six antioxidant genes significantly correlated with patient outcome, and high-risk patients (related to the six-gene signature including Prxl2a) had poorer prognosis [3].

In an Alzheimer's mouse model treated with cyanidin 3-O-glucoside, Prxl2a was among the upregulated antioxidant genes, suggesting its role in the antioxidant mechanism of the treatment [4].

In a mouse model of snakebite envenoming, Prxl2a was predicted as a biomarker sensitive to antivenom treatment, indicating its potential role in the pathophysiological changes after envenoming [5].

In conclusion, Prxl2a plays a crucial role in protecting cells from oxidative stress. Through gene-knockout or knockdown models in different disease conditions such as OSCC, endometrial cancer, kidney renal clear cell carcinoma, Alzheimer's disease, and snakebite envenoming, its functions in promoting tumor cell survival, affecting prognosis, and being involved in antioxidant and pathophysiological processes have been revealed. These findings contribute to a better understanding of the molecular mechanisms underlying these diseases and may provide potential therapeutic targets.

References:
1. Chen, Yi-Fen, Wei, Yun-Yen, Yang, Cheng-Chieh, Chang, Kuo-Wei, Lin, Shu-Chun. 2019. miR-125b suppresses oral oncogenicity by targeting the anti-oxidative gene PRXL2A. In Redox biology, 22, 101140. doi:10.1016/j.redox.2019.101140. https://pubmed.ncbi.nlm.nih.gov/30785086/
2. Yu, Jing, Yao, Hong-Wen, Liu, Ting-Ting, Ma, Sai, Wu, Ling-Ying. 2022. Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer. In Journal of personalized medicine, 12, . doi:10.3390/jpm12060914. https://pubmed.ncbi.nlm.nih.gov/35743699/
3. Ren, Xueting, Ma, Li, Wang, Nan, Kang, Huafeng, Zhou, Zhangjian. 2021. Antioxidant Gene Signature Impacts the Immune Infiltration and Predicts the Prognosis of Kidney Renal Clear Cell Carcinoma. In Frontiers in genetics, 12, 721252. doi:10.3389/fgene.2021.721252. https://pubmed.ncbi.nlm.nih.gov/34490047/
4. Jaiswal, Varun, Park, Miey, Lee, Hae-Jeung. 2021. Comparative Transcriptome Analysis of the Expression of Antioxidant and Immunity Genes in the Spleen of a Cyanidin 3-O-Glucoside-Treated Alzheimer's Mouse Model. In Antioxidants (Basel, Switzerland), 10, . doi:10.3390/antiox10091435. https://pubmed.ncbi.nlm.nih.gov/34573067/
5. Bala, Auwal A, Bedraoui, Anas, El Mejjad, Salim, Daouda, Tariq, Galan, Jacob A. 2025. Bioinformatics-Guided Identification and Quantification of Biomarkers of Crotalus atrox Envenoming and Its Neutralization by Antivenom. In Molecular & cellular proteomics : MCP, 24, 100956. doi:10.1016/j.mcpro.2025.100956. https://pubmed.ncbi.nlm.nih.gov/40147718/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Publications
Nature Communications
2025-07-15
Adipose tissue-derived PRXL2A suppresses hepatic lipogenesis in a study with male mice
Read More
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research